Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Clin Cancer Res. 2013 Mar 20;19(7):1873–1883. doi: 10.1158/1078-0432.CCR-12-2926

Figure 2.

Figure 2

Analysis of expression of p21CIP1, Mcl-1, and p-RNA Pol II in U937 cells treated with 1-μM vorinostat in the presence of 90% patient human plasma collected before and 24 h after alvocidib treatment. Samples are divided into 2 groups according to the 2 alvocidib infusion schemes used in this study i.e., (A) DSI and (B) WLMI. As a control, results of an in vitro experiment with U937 cells treated (24 h) with vorinostat (1 μM) and/or alvocidib (150 nM) are also shown. GAPDH is used as an internal loading control. The panel below represents a color scheme comparing results for the pre-treatment sample to results for the post-treatment sample. Red = down-regulation, green = up-regulation, and white = no change.